{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:08:13Z","timestamp":1779167293395,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013142","name":"Key Research and Development Project of Hainan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013142","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004761","name":"Hainan Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ijbiomac.2026.151067","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:11:39Z","timestamp":1771978299000},"page":"151067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Inhibition of replication factor C4-induced DNA damage repair reverses the chemoresistance of glioblastoma to temozolomide and reveals the synthetic lethal effect of combined targeting of checkpoint kinase 1"],"prefix":"10.1016","volume":"351","author":[{"given":"Ning","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duanyi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinzhe","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghua","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zezhou","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yansong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianpeng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jigao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiannong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ijbiomac.2026.151067_bb0005","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151067_bb0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/biomedicines7030069","article-title":"Temozolomide and other alkylating agents in glioblastoma therapy","volume":"7","author":"Strobel","year":"2019","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151067_bb0015","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s40478-025-02046-4","article-title":"Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights","volume":"13","author":"Li","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151067_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188616","article-title":"Elucidating the mechanisms of temozolomide resistance in gliomas and the strategies to overcome the resistance","volume":"1876","author":"Tomar","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.151067_bb0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-med-081313-121208","article-title":"The DNA damage response: implications for tumor responses to radiation and chemotherapy","volume":"66","author":"Goldstein","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151067_bb0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151067_bb0035","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1038\/s41467-023-39845-z","article-title":"Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2026.151067_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117411","article-title":"Discovery of a novel Wnt inhibitor DK419: reversing temozolomide resistance in glioblastoma by switching off Wnt\/\u03b2-catenin signaling pathway to inhibit MGMT expression","volume":"288","author":"Bai","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2026.151067_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116886","article-title":"Natural small molecule thymoquinone increases the chemosensitivity of glioblastoma to temozolomide through inhibiting Wnt\/\u03b2-catenin signaling pathway to downregulate MGMT expression: in vitro and in vivo validation","volume":"236","author":"Bai","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"767","key":"10.1016\/j.ijbiomac.2026.151067_bb0050","doi-asserted-by":"crossref","first-page":"eado1573","DOI":"10.1126\/scitranslmed.ado1573","article-title":"Dynamic structural remodeling of LINC01956 enhances temozolomide resistance in MGMT-methylated glioblastoma","volume":"16","author":"Liao","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151067_bb0055","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41392-023-01548-8","article-title":"A new wave of innovations within the DNA damage response","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151067_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021263","article-title":"Key proteins of replication stress response and cell cycle control as cancer therapy targets","volume":"25","author":"Khamidullina","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151067_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167574","article-title":"Molecular mechanisms restoring olaparib efficacy through ATR\/CHK1 pathway inhibition in olaparib-resistant BRCA1\/2MUT ovarian cancer models","volume":"1871","author":"Biega\u0142a","year":"2025","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151067_bb0070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jmb.2011.12.017","article-title":"A central swivel point in the RFC clamp loader controls PCNA opening and loading on DNA","volume":"416","author":"Sakato","year":"2012","journal-title":"J. Mol. Biol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151067_bb0075","doi-asserted-by":"crossref","first-page":"478","DOI":"10.21873\/cgp.20515","article-title":"Replication factor C subunit 4 plays a role in human breast cancer cell progression","volume":"22","author":"Koh","year":"2025","journal-title":"Cancer Genomics Proteomics"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151067_bb0080","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/2211-5463.13929","article-title":"Knockdown of RFC4 inhibits cell proliferation of oral squamous cell carcinoma in vitro and in vivo","volume":"15","author":"You","year":"2025","journal-title":"FEBS Open Bio"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151067_bb0085","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11684-022-0938-x","article-title":"Knockdown of RFC4 inhibits the cell proliferation of nasopharyngeal carcinoma in vitro and in vivo","volume":"17","author":"Guan","year":"2023","journal-title":"Front. Med."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151067_bb0090","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1021\/acs.jproteome.4c00885","article-title":"Investigating cisplatin resistance in squamous cervical cancer: proteomic insights into DNA repair pathways and omics-based drug repurposing","volume":"24","author":"Mukherjee","year":"2025","journal-title":"J. Proteome Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151067_bb0095","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1038\/s41467-021-22971-x","article-title":"An RFC4\/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.151067_bb0100","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41417-022-00519-5","article-title":"Correction: Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4","volume":"29","author":"Hu","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151067_bb0105","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ijc.28226","article-title":"Roles of Chk1 in cell biology and cancer therapy","volume":"134","author":"Zhang","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.151067_bb0110","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1002\/ijc.22198","article-title":"Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics","volume":"119","author":"Chen","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151067_bb0115","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother. Oncol."},{"issue":"17","key":"10.1016\/j.ijbiomac.2026.151067_bb0120","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: a clinical review","volume":"310","author":"Omuro","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.151067_bb0125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2176\/nmc.ra.2018-0141","article-title":"Potential strategies overcoming the temozolomide resistance for glioblastoma","volume":"58","author":"Jiapaer","year":"2018","journal-title":"Neurol. Med. Chir. (Tokyo)"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151067_bb0130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11912-021-01077-z","article-title":"DNA repair mechanisms and therapeutic targets in glioma","volume":"23","author":"Elmore","year":"2021","journal-title":"Curr. Oncol. Rep."},{"issue":"Pt 2","key":"10.1016\/j.ijbiomac.2026.151067_bb0135","article-title":"Novel strategies to overcome chemoresistance in human glioblastoma","volume":"230","author":"Tang","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151067_bb0140","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1021\/acsptsci.4c00085","article-title":"Energy blocker lonidamine reverses nimustine resistance in human glioblastoma cells through energy blockade, redox homeostasis disruption, and O6-methylguanine-DNA methyltransferase downregulation: in vitro and in vivo validation","volume":"7","author":"Huang","year":"2024","journal-title":"ACS Pharmacol Transl Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151067_bb0145","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41401-022-00971-x","article-title":"Author correction: Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle","volume":"44","author":"Ren","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"issue":"7782","key":"10.1016\/j.ijbiomac.2026.151067_bb0150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2026.151067_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100796","article-title":"Anticancer drug resistance: an update and perspective","volume":"59","author":"Nussinov","year":"2021","journal-title":"Drug Resist. Updat."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151067_bb0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1478-3231.2008.01792.x","article-title":"The knockdown of endogenous replication factor C4 decreases the growth and enhances the chemosensitivity of hepatocellular carcinoma cells","volume":"29","author":"Arai","year":"2009","journal-title":"Liver Int."},{"issue":"23","key":"10.1016\/j.ijbiomac.2026.151067_bb0165","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/s41388-025-03454-5","article-title":"Post-translational modifications in DNA damage repair: mechanisms underlying temozolomide resistance in glioblastoma","volume":"44","author":"Chen","year":"2025","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151067_bb0170","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41420-024-02085-1","article-title":"The combination of temozolomide and perifosine synergistically inhibit glioblastoma by impeding DNA repair and inducing apoptosis","volume":"10","author":"Zhao","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ijbiomac.2026.151067_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115726","article-title":"Modulating MGMT expression through interfering with cell signaling pathways","volume":"215","author":"Bai","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151067_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2013.10.005","article-title":"CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy","volume":"142","author":"McNeely","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.151067_bb0185","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1007\/s00018-013-1307-3","article-title":"Checkpoint kinase 1 in DNA damage response and cell cycle regulation","volume":"70","author":"Patil","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.151067_bb0190","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.18632\/oncotarget.26583","article-title":"LATS1\/2 kinases trigger self-renewal of cancer stem cells in aggressive oral cancer","volume":"10","author":"Nozaki","year":"2019","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151067_bb0195","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/cdd.2011.170","article-title":"Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy","volume":"19","author":"Bartucci","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ijbiomac.2026.151067_bb0200","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1186\/1471-2407-14-570","article-title":"Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers","volume":"14","author":"Bryant","year":"2014","journal-title":"BMC Cancer"},{"issue":"445","key":"10.1016\/j.ijbiomac.2026.151067_bb0205","doi-asserted-by":"crossref","first-page":"ra90","DOI":"10.1126\/scisignal.aac9704","article-title":"CHK1 as a therapeutic target to bypass chemoresistance in AML","volume":"9","author":"David","year":"2016","journal-title":"Sci. Signal."},{"issue":"23","key":"10.1016\/j.ijbiomac.2026.151067_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239034","article-title":"Checkpoint kinase 1 pharmacological inhibition synergizes with DNA-damaging agents and overcomes platinum resistance in basal-like breast cancer","volume":"21","author":"Nieto-Jimenez","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151067_bb0215","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1158\/1541-7786.MCR-19-0934","article-title":"Constitutive CHK1 expression drives a pSTAT3-CIP2A circuit that promotes glioblastoma cell survival and growth","volume":"18","author":"Khanna","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.151067_bb0220","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/CAD.0000000000000278","article-title":"Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors","volume":"26","author":"Doi","year":"2015","journal-title":"Anti-Cancer Drugs"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151067_bb0225","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s10637-012-9815-9","article-title":"Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg\/m(2) every 21 days in patients with cancer","volume":"31","author":"Weiss","year":"2013","journal-title":"Investig. New Drugs"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151067_bb0230","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/neuonc\/noab003","article-title":"PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma","volume":"23","author":"Wu","year":"2021","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.ijbiomac.2026.151067_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18632\/oncotarget.28551","article-title":"ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines","volume":"15","author":"Lozinski","year":"2024","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151067_bb0240","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1158\/1535-7163.MCT-17-1267","article-title":"The DNA-PK inhibitor VX-984 enhances the radiosensitivity of glioblastoma cells grown Iin vitro and as orthotopic xenografts","volume":"17","author":"Timme","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151067_bb0245","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163447","article-title":"Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment","volume":"133","author":"Arrieta","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151067_bb0250","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12943-024-02147-z","article-title":"Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors","volume":"23","author":"Murray","year":"2024","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151067_bb0255","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12032-022-01657-4","article-title":"Glioblastoma recurrent cells switch between ATM and ATR pathway as an alternative strategy to survive radiation stress","volume":"39","author":"Kaur","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.151067_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106162","article-title":"Cell cycle checkpoints and beyond: exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer","volume":"178","author":"Gupta","year":"2022","journal-title":"Pharmacol. Res."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026009931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026009931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:18:58Z","timestamp":1779164338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026009931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":52,"alternative-id":["S0141813026009931"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151067","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of replication factor C4-induced DNA damage repair reverses the chemoresistance of glioblastoma to temozolomide and reveals the synthetic lethal effect of combined targeting of checkpoint kinase 1","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151067"}}